Blood-based testing of mutations in patients with head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology
Florentia Fostira(National Centre of Scientific Research "Demokritos"), Amanda Psyrri(National and Kapodistrian University of Athens), Elena Vagia Vagia(University General Hospital Attikon), Denise Heim(Sysmex (Germany)), Evgenia Kousidou(University General Hospital Attikon), Athina Kladi(University General Hospital Attikon), Kristin Stieler(Sysmex (Germany)), Μaria Anastasiou(National and Kapodistrian University of Athens), Μαρία Γκοτζαμανίδου(National and Kapodistrian University of Athens), George Kavourakis(National and Kapodistrian University of Athens), P. Oikonomopoulou(University General Hospital Attikon), Daniel L. Edelstein(Sysmex (Japan)), Frank Holtrup(Sysmex (Germany)), Ioannis Kotsantis(National and Kapodistrian University of Athens), Niki Gavrielatou(National and Kapodistrian University of Athens)
Cited by 4
Related Papers
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Head and neck squamous cell cancer and the human papillomavirus: Summary of a National Cancer Institute State of the Science Meeting, November 9–10, 2008, Washington, D.C.
|Head & Neck|2009|265
Blood‐based detection of <i><scp>RAS</scp></i> mutations to guide anti‐<scp>EGFR</scp> therapy in colorectal cancer patients: concordance of results from circulating tumor <scp>DNA</scp> and tissue‐based <i><scp>RAS</scp></i> testing
|Molecular Oncology|2017|161
The Role of Phosphoinositide 3-Kinase C2α in Insulin Signaling
|Journal of Biological Chemistry|2007|155